I en lille observationsgruppe fik 280 patienter med reumatoid arthritis efterfølgende behandling med andre DMARDs, og deraf fik 185 patienter et biologisk DMARD efter MabThera behandling.
In a small cohort of patients with rheumatoid arthritis, 280 patients received subsequent therapy with other DMARDs of whom 185 received a biologic DMARD following MabThera.